TS-ONE
  • About TS-ONE ®
  • Patient Information
  • Useful Information
  • Contact

  • 1. What’s TS-ONE ®

  • 2. Approved Countries

  • 3. Scientific Information

  • 4. Administration

Phase III Studies and Guideline Recommendations*


Gastric Cancer

Colorectal Cancer

Pancreatic Cancer

Biliary Tract Cancer

Lung Cancer

Breast Cancer

Head and Neck Cancer


* In Hong Kong, TS-ONE ® is indicated for post operative adjuvant chemotherapy for locally advanced (stage II (excluding T1), IIIA or IIIB) gastric cancer 2.

Breast Cancer
  • Toi M. et al., Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021 Jan;22(1), pp. 74-84.
  • Shimoi T. et al. 2020 The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition.
    Breast Cancer, 27, 322-331(2020).
  • Takashima T. et al., 2016. Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial.
    Lancet Oncol., 17(1), pp.90-98.

This Site is intended for Hong Kong healthcare professionals only. Products discussed herein may have different labeling in different countries. TS-ONE® is a registered trademark of TAIHO PHARMACEUTICAL CO., LTD. and used under license. Copyright © TAIHO PHARMACEUTICAL CO., LTD. 2020 All rights reserved.